资讯内容 Content

[ASCO2015]慢性淋巴细胞白血病与分子靶向治疗——美国俄亥俄州立大学医学中心Jeffrey A. Jones教授访谈
 编辑:肿瘤瞭望 时间:2015/5/30 18:58:10 关键字:慢性淋巴细胞白血病 分子靶向治疗 激酶抑制剂 

  Oncology Frontier: Abstract Richter syndrome (RS) or Richter transformation is the development of secondary aggressive. What progress has been made in understanding the genetic events which relate to progression of CLL or transformation into RS?

  《肿瘤瞭望》:Richter综合征或者Richter转变是在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的背景中,继发的侵袭性淋巴瘤。对该转变的基因改变研究有无最新进展?

 

  Dr Jones: In general, the mechanism by which CLL transforms to high-grade lymphoma, Richter transformation, is not clear. The specific mechanism has not been elucidated. But who are the patients who are at greatest risk? This is the same group of patients who are at higher risk of relapsed and refractory CLL. We know there is an association between IGH mutation status and cytogenetics particularly with deletion 17p, so these patients are over-represented in the group that develop Richter transformation.

  Jones教授:总体来说,CLL转化成高级别的淋巴瘤、Richter转化的机制并不清楚。IGH突变、del(17p)的患者是上述转化的高危人群。

 



上一页  [1]  [2]  [3]  [4]  下一页

点击排行 Top Hits

相关幻灯

相关视频

 
关于本站 | 设为首页 | 加入收藏 | 站长邮箱 | 友情链接 | 版权申明

肿瘤瞭望 版权所有  2014-2019 ioncol.com  All Rights Reserved